Catheter Precision, a U.S.-based medical device company, reported impressive financial growth in Q3 2025.
Total revenue for the company increased by 135% in Q3 2025 compared to Q3 2024, reaching $226,000.
The GAAP net loss for Q3 2025 reduced by 45% from Q3 2024, showcasing improved financial performance.
Revenue Growth
Total revenue in Q3 2025 increased by 135% compared to Q3 2024, reaching $226,000.
International Sales Expansion
Sales activities for LockeT and VIVO are expanding outside the US, with increased interest and orders from countries like South Africa and France.
Clinical Prioritization
The focus on clinical studies and publications underscores the company's commitment to advancing healthcare solutions.
Future Growth Expectations
CEO David Jenkins anticipates significant growth in product lines across domestic and international markets, relying on positive clinical study results for VIVO.
- Increased international sales indicate growing global acceptance of Catheter Precision's products.
- Positive financial results reflect the company's strategic initiatives and product performance.
- Clinical studies and publication mentions enhance the company's reputation in the electrophysiology marketplace.
Catheter Precision's strong financial performance and global expansion efforts position it for continued growth in the medical device industry.